Pregnancy follow-up after patisiran exposure
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This program tracks pregnancy outcomes for people who were exposed to patisiran (a medicine) in a special delivery form called LNP during pregnancy or shortly before. It helps doctors understand potential effects and safety for mothers and babies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have documentation showing you were exposed to patisiran-LNP
- The exposure happened any time starting 12 weeks before your last menstrual period (LMP)
- Or the exposure happened during your pregnancy
- There are no listed reasons you must be excluded
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows pregnant people who either took TEGSEDI or did not take it, to better understand pregnancy outcomes in transthyretin amyloid polyneuropathy (hATTR-PN). Your participation may help doctors guide safer pregnancy care for people with this condition.
This trial tests a new medicine called nucresiran for people with a rare genetic nerve condition (hATTR-PN). The goal is to see if it can slow down or improve nerve damage.
This study tracks the safety of eplontersen during pregnancy and breastfeeding by collecting reports from people who have taken it. It helps doctors understand any risks to the baby or mother.
This trial tests whether the drug tafamidis can help people with a specific type of nerve damage caused by abnormal protein buildup. It aims to slow or improve symptoms in adults with this condition.
This study tests a drug called vutrisiran for people with a condition called transthyretin amyloidosis that affects the heart. It is for patients who have already been in certain earlier studies of patisiran or vutrisiran.
This study follows people after they had a NIPT blood test during pregnancy to better understand outcomes. If you were tested through Sequenom/Integrated Genetics and your pregnancy outcome is known, you may be eligible.
Hear when a new Hereditary Transthyretin-mediated (hATTR) Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.